1234366-97-2

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-bromophenyl)-2-((2,4-dichlorobenzyl)(methyl)amino)ethanol is used as a pharmaceutical compound for its potential pharmacological properties. The presence of the ethanol and methylamine groups may contribute to its interaction with biological targets, making it a candidate for drug development.
Used in Organic Synthesis:
In the field of organic synthesis, 1-(3-bromophenyl)-2-((2,4-dichlorobenzyl)(methyl)amino)ethanol can be utilized as a chemical intermediate. Its bromine and chlorine substituents, along with the amine group, offer opportunities for further chemical reactions to produce a variety of derivative compounds.
Used in Chemical Research:
1-(3-bromophenyl)-2-((2,4-dichlorobenzyl)(methyl)amino)ethanol may also be employed in chemical research as a model or starting material to study the effects of different functional groups on a molecule's reactivity, stability, and potential applications in material science or medicinal chemistry.

Upstream product

• 1234366-96-1 1-(3-bromophenyl)-2-((2,4-dichlorobenzyl)(methyl)amino)ethanone 

Downstream Products

• 543737-10-6 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS

The present disclosure is directed to corn- pounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/ or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract